Khushboo Daga, CEO

Siddharth Daga, Managing Director

In the heart of the pharmaceutical landscape lies a realm where every vial, every dose, holds the potential to save a life. This is the world of antisera against snake and scorpion bites, tetanus, diphtheria, gangrene antitoxins, and rabies immunoglobulins — the unsung heroes of emergency medicine. From the sun-scorched plains of sub-Saharan Africa to the teeming metropolis of Asia, the demand for these specialized interventions echoes the urgent call of those in need. The relentless onslaught of venomous bites, bacterial infections, and viral exposures knows no bounds, yet amidst the chaos, a beacon of hope emerges — the promise of timely intervention, of swift action, of lives spared.

But behind this promise lie formidable challenges. The path to accessibility is fraught with hurdles — from the remote corners where access to quality-assured medications is but a distant dream to the bustling urban centers grappling with the specter of vaccine hesitancy and antimicrobial resistance. A new dawn beckons in the corridors of research labs and manufacturing facilities. Collaborations between governments, healthcare providers, and pharmaceutical innovators pave the way for production, distribution, and affordability breakthroughs. Digitalization and advanced technologies revolutionize quality assurance and supply chain management, ensuring that every dose meets the highest efficacy and safety standards. But beyond the realm of science lies the heart of the matter — the human stories that underscore the significance of these life-saving interventions. From the child spared the agony of tetanus to the farmer whose livelihood is safeguarded from the venomous fangs of a snake, the impact reverberates far and wide. In this landscape of life-saving miracles, VINS Bioproducts emerges as a guiding light, weaving a tapestry of hope and healing with its pioneering injectable medications.

With a legacy spanning over 27 years, VINS Bioproducts has carved a niche for itself as a leading manufacturer of injectable medications, specializing in antisera against snake and scorpion bites, tetanus, diphtheria, gangrene antitoxins, and rabies immunoglobulins. In the wake of the COVID-19 pandemic, heightened awareness and a growing interest in understanding the necessity of pharmaceuticals have further underscored the significance of its contributions. This increased consciousness has simplified the company’s efforts to raise awareness about its products, enabling more informed consumer decision-making. "The technology we utilize is the sole method for crafting medications to combat snakebites, diphtheria, and other critical ailments”, says Siddharth Daga, Managing Director at VINS Bioproducts. "There exists no alternative to this proven methodology, through which we have mastered all essential parameters", he further adds.

A Strong Foundation

In VINS Bioproducts, a robust team comprising over 200 scientists operate across diverse quality assurance, control, and production departments. Complementing this workforce is an expansive equine farm housing over 2000 equines, supported by a team of 15 veterinarians and 20 para-vets. In addition, a dedicated labor force of 400 individuals is assigned to defined facilities, with an additional 200 personnel allocated to manufacturing facilities. Ensuring product quality and efficacy maintenance is paramount, and a strong belief in digitalization underpins the company’s approach. By leveraging software-driven processes, documentation is streamlined to minimize paperwork, with every quality control and assurance document subject to a compliant software system, adhering to 21 CFR standards. This meticulous approach fosters transparency, instilling confidence in regulatory bodies and personnel.

Furthermore, the company employs advanced technologies, including double chromato­graphic systems for product pu­rification, a method less common in vaccine manufacturing. With end-to-end testing capabilities spanning from interme­diate to finished product levels and accreditation by PICS, the company’s global reach extends to over 110 countries. Regu­lar inspections, averaging at least twice monthly, underscore their commitment to maintaining quality and documentation standards. These measures, tailored to the exigencies of life-saving pharmaceuticals, support their unwavering commit­ment to excellence in the market.

Empowering Health Globally

The impact of VINS Bioproducts extends far beyond the bustling streets of Mumbai, reaching the far-flung corners of Southeast Asia and beyond. In remote villages with limited access to healthcare, the company’s interventions have been lifesaving, offering relief and protection against deadly ailments. Amidst the chaos of the COVID-19 pandemic, VINS Bioproducts demonstrated unparalleled resilience and determination. Teaming up with prestigious institutions such as the Centre for Cellular & Molecular Biology (CCMB) and the University of Hyderabad, it embarked on a groundbreaking journey to develop an indigenous antidote for COVID-19. This collaborative effort underscored its scientific acumen and reaffirmed the company’s unwavering commitment to global health. By pioneering an antidote in the face of a worldwide crisis, VINS Bioproducts proved reliable in uncertain times.

However, more than the scientific innovations distinguish VINS Bioproducts. Its ethos of compassion and solidarity permeates every aspect of its work. A poignant example of this is its intervention in Southeast Asia. A prevalent issue of snake bites plagued communities, exacerbated by the region’s susceptibility to floods. Compounded by a small population, establishing a manufacturing plant seemed unfeasible, given the erratic demand and logistical challenges. Recognizing this plight during a visit, VINS Bioproducts’ representative empathized with the

plight, particularly affecting vulnerable farming communities. Engaging with government officials, a compassionate solution emerged: offering the necessary antidote as a stockpile, free of charge for the initial consignment. This gesture alleviated financial concerns and instilled newfound confidence in the populace. Witnessing the antidote’s impact on saving lives, especially among children, pregnant women, and farmers, local authorities were deeply moved. Grateful for the company’s benevolence, they reciprocated with unwavering support, cementing a partnership rooted in compassion and solidarity.

Saving Lives, Sustaining Futures

Ensuring seamless distribution, VINS Bioproducts meticulous­ly orchestrates its supply chain logistics. With distribu­tion centers spanning 15,000 square feet and equipped with automated packaging lines, the company guar­antees swift delivery to every corner of the nation. Through strategic partnerships with local hospitals and awareness campaigns, such as the CME programs in Telangana, the company not only disseminates vi­tal information but also ensures prompt access to life-saving medication within 30 minutes.

Demonstrating a steadfast commitment to sustainability, VINS Bioproducts integrates eco-friendly practices into its operations. From minimizing single-use plastics in equine plasma collection to harnessing solar energy through an in-house half-megawatt solar plant, the company champions environmental stewardship. In addition, through initiatives like organic fodder cultivation and hydroponic farming, the company ensures the well-being of its equine companions and fosters a greener tomorrow.

They boast a dynamic, youthful team at VINS Bioproducts, comprising individuals aged 45 and below, each bringing 15 to 25 years of professional expertise. “My mother is involved in the business; she takes care of the animals. My wife, Khushboo, takes care of the entire segment of the key business development aspects, including new business opportunities", says Daga. With a growth rate of nearly 40 percent and ambitious expansion plans, the company envisions a future where it stands as the premier life-saving manufacturer globally. Through compassion, sustainability, and unwavering dedication, VINS Bioproducts continues redefining the landscape of pharmaceutical excellence.